You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5317 Results
Statistical Reports
Document
May 2020
Document
May 2020
Document
May 2020
Document
May 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
riTUXimab,
CISplatin,
cytarabine,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2020
Document
May 2020
Document
May 2020
Document
May 2020
Document
May 2020
Document
May 2020
Document
May 2020

Pages